Performance of high-dose omalizumab in chronic urticaria is predicted by initial improvement to standard dose

J Allergy Clin Immunol Pract. 2024 Jun 19:S2213-2198(24)00637-8. doi: 10.1016/j.jaip.2024.06.014. Online ahead of print.
No abstract available